

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human LILRB3/CD85a/ILT5 in direct ELISAs and Western blots. In direct ELISAs, no cross-reactivity with recombinant human (rh) ILT1, rhILT2, rhILT3, rhILT4, rhILT6, rhILT7 or rhILT11 is observed.
Source	Monoclonal Mouse IgG _{2A} Clone # 222821
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	Mouse myeloma cell line NS0-derived recombinant human LILRB3/CD85a/ILT5 Gly24-Glu443 Accession # AAB68668
Conjugate	Alexa Fluor 647 Excitation Wavelength: 650 nm Emission Wavelength: 668 nm
Formulation	Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide. See Certificate of Analysis for details. *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	Recommended Concentration	Sample
Flow Cytometry	0.25-1 µg/10 ⁶ cells	Human peripheral blood mononuclear cells (PBMCs)

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. <ul style="list-style-type: none"> 12 months from date of receipt, 2 to 8 °C as supplied.

BACKGROUND

Immunoglobulin-Like Transcript 5 (ILT5), also known as Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB3), leukocyte immunoglobulin-Like Receptor 3 (LIR3) and CD85a, is an Ig-like receptor family member that is involved in immune regulation. ILT5 belongs to subfamily B whose members have cytoplasmic tails that contain Immunoreceptor Tyrosine-based Inhibitory Motifs (ITIMs) that inhibit signaling events via phosphatase SHP-1. The counterpart to subfamily B is subfamily A, whose members qualify as activating receptors that lack ITIMs, but signal through association with Fcγ. ILTs share structural homology and chromosomal localization with the KIR family of receptors (1, 2). Mature ILT5 is a highly polymorphic 85-95 kDa glycoprotein that consists of a 420 amino acid (aa) extracellular domain (ECD) with four Ig-like domains, a 21 aa transmembrane segment, and a 167 aa cytoplasmic domain with three ITIMs (3, 4). Alternate splicing generates an isoform with a 17 aa insertion in the juxtamembrane ECD. In mouse and rat, the LILRB3 gene encodes the PIR-B protein which has six Ig-like domains. Rodent PIR-B and human ILT5 share 55% aa sequence identity within common regions of their ECDs. Both PIR-B and ILT5 are receptors for *S. aureus*, and activation of these receptors by bacteria influences the innate immune response triggered by TLRs (4). ILT5 is expressed on the surface of peripheral monocytes, neutrophils, eosinophils, basophils, and mast cell progenitors but not on mature mast cells (5-7). On basophils, cross-linking of ILT5 to the activating receptors ILT1/LIR7 or FcεRI inhibits the release of Histamine, Leukotriene C4, and IL-4 (6). On osteoclast precursors, ILT5 ligation inhibits RANKL or M-CSF induced differentiation (8). ILT5 is down-regulated on macrophages in rheumatoid arthritis synovial tissue following successful treatment with DMARD anti-rheumatic drugs (9).

References:

1. Brown, D. *et al.* (2004) *Tissue Antigens* **64**:215.
2. Borges, L. and D. Cosman (2000) *Cytokine Growth Factor Rev.* **11**:209.
3. SwissProt Accession # O75022.
4. Nakayama, M. *et al.* (2007) *J. Immunol.* **178**:4250.
5. Tedla, N. *et al.* (2003) *Proc. Natl. Acad. Sci.* **100**:1174.
6. Sloane, D.E. *et al.* (2004) *Blood* **104**:2832.
7. Tedla, N. *et al.* (2008) *J. Leukoc. Biol.* **83**:334.
8. Mori, Y. *et al.* (2008) *J. Immunol.* **181**:4742.
9. Huynh, O.A. *et al.* (2007) *Rheumatology* **46**:742.

Human LILRB3/CD85a/ILT5 Alexa Fluor® 647-conjugated Antibody

Monoclonal Mouse IgG_{2A} Clone # 222821

Catalog Number: FAB1806R
100 µg

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.